| Metric | Value ($ M) | Q1 FY25 |
|---|---|---|
| Revenue | 6.15 | 15.1% |
| Total Income | 6.15 | 15.1% |
| Expenditure | 33.94 | 6.8% |
| PBT | — | |
| Net Profit | -25.13 | 4.5% |
| OPM | — | |
| NPM | — | |
| EPS | -0.20 | 46.0% |
C4 Therapeutics Reports Q1 2026 Financial Results
12 May 2026 · 12 May, 4:41 pm
Summary
C4 Therapeutics, Inc. reported financial results for the first quarter ended March 31, 2026. The company's total revenue for the quarter was $6.2 million, compared to $7.2 million for the first quarter of 2025. Net loss for the quarter was $25.1 million, compared to $26.3 million for the first quarter of 2025. As of March 31, 2026, cash, cash equivalents and marketable securities totaled $268.3 million, which is expected to fund operations to the end of 2028.
Key Highlights
- 1
C4 Therapeutics reported cash, cash equivalents and marketable securities of $268.3 million as of March 31, 2026.
- 2
First patient was dosed in the Phase 2 MOMENTUM trial in February 2026.
- 3
Total revenue for the first quarter of 2026 was $6.2 million, compared to $7.2 million for the first quarter of 2025.
- 4
Net loss for the first quarter of 2026 was $25.1 million, compared to $26.3 million for the first quarter of 2025.
- 5
Net loss per share for the first quarter of 2026 was $0.20, compared to $0.37 for the first quarter of 2025.
- 6
The company expects that its current cash, cash equivalents and marketable securities will fund its operations to the end of 2028.
- 7
C4T entered into a new collaboration agreement with Roche in April 2026, receiving an upfront payment of $20 million in May 2026.
Management Comments
Andrew Hirsch
“During the first quarter, we made strong progress advancing cemsidomide as a potential best-in-class IKZF1/3 degrader for the treatment of multiple myeloma, highlighted by the initiation of two new clinical trials and plans to begin an additional combination trial next year. We believe our clinical development path further supports the advancement of IKZF1/3 degradation - the only mechanism targeting a central transcriptional dependency in multiple myeloma -and will help position cemsidomide as a potentially foundational therapy for these patients with relapsed refractory disease. In addition to these clinical advances, we also expanded our partnership with Roche through a new collaboration focused on degrader‑antibody conjugates, broadening the reach of targeted protein degradation in cancer. Supported by a strong balance sheet through key value inflection points, we remain focused on advancing our portfolio to deliver the next generation of targeted protein degrader medicines to patients.”
Informational and educational content only. Not investment advice.